Position in REPL
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$5,484,797
+$20,976 QoQ
Shares Held
495,465
-30.6% QoQ
Ownership
0.526%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#37
of 199 holders
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REPL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names. REPL ranks #22 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,357,042 | $110,693,915 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $80,947,193 | |
| 3 | IMTX |
Immatics N.V.
|
6,506,802 | $65,913,904 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
2,010,534 | $62,849,292 | |
| 5 | CGON |
CG Oncology, Inc.
|
769,947 | $54,704,734 | |
| 6 | ARGX |
Argenx SE
|
45,068 | $41,812,738 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
929,626 | $31,040,212 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
466,258 | $26,679,282 |
All Filings in REPL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,484,797 | 495,465 | Shares | Defined | 2026-08-17 | |
| 2026-03-31 | $5,463,821 | 714,225 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $6,942,276 | 714,226 | Shares | Defined | 2026-02-09 | |
| 2024-06-30 | $9,000,000 | 1,000,000 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $8,170,000 | 1,000,000 | Shares | Defined | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||